These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21128825)

  • 1. Janus kinase 2 inhibitors in myeloproliferative disorders.
    Lucia E; Recchia AG; Gentile M; Bossio S; Vigna E; Mazzone C; Madeo A; Morabito L; Gigliotti V; De Stefano L; Caruso N; Servillo P; Franzese S; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Jan; 20(1):41-59. PubMed ID: 21128825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.
    Pardanani A
    Leukemia; 2008 Jan; 22(1):23-30. PubMed ID: 17882282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
    Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
    Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2 kinase inhibitors and myeloproliferative disorders.
    Chen AT; Prchal JT
    Curr Opin Hematol; 2010 Mar; 17(2):110-6. PubMed ID: 20087176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of JAK2 inhibitors.
    Verstovsek S
    Hematology Am Soc Hematol Educ Program; 2009; ():636-42. PubMed ID: 20008249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
    Garber K
    J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
    [No Abstract]   [Full Text] [Related]  

  • 7. Preclinical and clinical activity of ATP mimetic JAK2 inhibitors.
    Wadleigh M; Tefferi A
    Clin Adv Hematol Oncol; 2010 Aug; 8(8):557-63. PubMed ID: 20966892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
    Stein BL; Crispino JD; Moliterno AR
    Curr Opin Oncol; 2011 Nov; 23(6):609-16. PubMed ID: 21993415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic approaches in myelofibrosis.
    Barosi G; Rosti V; Vannucchi AM
    Expert Opin Pharmacother; 2011 Jul; 12(10):1597-611. PubMed ID: 21457082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.
    Quintás-Cardama A
    Leuk Res; 2013 Apr; 37(4):465-72. PubMed ID: 23313046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [JAK2 inhibitors in the treatment of myeloproliferative neoplasms].
    Shide K
    Rinsho Ketsueki; 2012 Oct; 53(10):1600-7. PubMed ID: 23037732
    [No Abstract]   [Full Text] [Related]  

  • 14. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
    Kirabo A; Park SO; Majumder A; Gali M; Reinhard MK; Wamsley HL; Zhao ZJ; Cogle CR; Bisht KS; Keserü GM; Sayeski PP
    Neoplasia; 2011 Nov; 13(11):1058-68. PubMed ID: 22131881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of two new chemotypes for inhibiting the Janus kinase 2 by scaffold morphing.
    Furet P; Gerspacher M; Pissot-Soldermann C
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1858-60. PubMed ID: 20172718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments on JAK2 inhibitors: a patent review.
    Kiss R; Sayeski PP; Keserũ GM
    Expert Opin Ther Pat; 2010 Apr; 20(4):471-95. PubMed ID: 20205617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.
    Lim J; Taoka B; Otte RD; Spencer K; Dinsmore CJ; Altman MD; Chan G; Rosenstein C; Sharma S; Su HP; Szewczak AA; Xu L; Yin H; Zugay-Murphy J; Marshall CG; Young JR
    J Med Chem; 2011 Oct; 54(20):7334-49. PubMed ID: 21942426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
    Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
    Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
    Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
    Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
    Atallah E; Verstovsek S
    Expert Rev Anticancer Ther; 2009 May; 9(5):663-70. PubMed ID: 19445582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.